Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold

Current Topics in Medicinal Chemistry

Volumn 10, Issue 7, 2010, Pages 752-766

  Teno, Naoki ^a,b   Masuya, Keiichi ^a,c  

^a Novartis Institutes for BioMedical Research   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone marrow; Bone resorption; C terminal telopeptide of type I collagen; Non peptidic cathepsin K inhibitors; Pyrrolopyrimidine scaffold; Spiro structure

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CATHEPSIN K INHIBITOR; NITRILE; PYRROLOPYRIMIDINE DERIVATIVE; SCAFFOLD PROTEIN;

ARTICLE; BONE ATROPHY; BONE MARROW; BONE MASS; CARBOXY TERMINAL SEQUENCE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BONE RESORPTION; CATHEPSIN K; CYSTEINE PROTEINASE INHIBITORS; HUMANS; OSTEOPOROSIS; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952474536     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791113423     Document Type: Article

References (68)

1. Lecaille, F.; Kaleta, J.; Brömme, D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev., 2002, 102, 4459-4488.
2. Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev., 2002, 102, 4501-4523.
3. Okada, Y.; Tsuda, Y.; Teno, N.; Wanaka, K.; Bohgaki, M.; Hijikata-Okunomiya, A.; Naitoh, T.; Okamoto, S. Synthesis of active center-directed peptide inhibitors of plasmin. Chem. Pharm. Bull., 1988, 36, 1289-1297.
4. Hekim, C.; Leinonen, J.; Närvänen, A.; Koistinen, H.; Zhu, L.; Koivunen, E.; Väisänen, V.; Stenman, U-H. Novel peptide inhibitors of human kallikrein 2. J. Biol. Chem., 2006, 281, 12555-12560.
5. Kosugi, S.; Hasebe, M.; Entani, T.; Takayama, S.; Tomita, M.; Yanagawa, H. Design of peptide inhibitors for the importin α/β nuclear import pathway by activity-based profiling. Chem. Biol, 2008, 15, 940-949.
6. Donkor, I. O. A survey of calpain Inhibitors. Curr. Med. Chem., 2000, 7, 1171-1188.
7. Yin, Z.; Patel, S. J.; Wang, W. L.; Wang, G.; Chan, W. L.: Rao, K. R.; Alam, J.; Jeyaraj, D. A.; Ngew, X.; Patel, V.; Beer, D.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. Peptide inhibitors of dengue virus NS3 protease. part 1: warhead. Bioorg. Med. Chem. Lett., 2006, 16, 36-39.
8. Ettari, R.; Nizi, E.; Francesco, M. E. D.; Dude, M-A.; Pradel, G.; Vicík, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappalà, M. Development of Peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. J. Med. Chem., 2008, 51, 988-996.
9. Lin, C.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Wei, Y.-Y.; Brennan, D. L.; Fulghum, J. R.; Hsaio, H.-M.; Ma, S.; Maxwell, J. P.; Cottrell, K. M.; Perni, R. B.; Gates, C. A.; Kwong, A. D. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem., 2004, 279, 17508-17514.
10. Peters, J.-U. 11 years of cyanopyrrolidines as DPP-IV inhibitors. Curr. Top. Med. Chem., 2007, 7, 579-595.
11. Tezuka, K.; Tezuka, Y.; Maejima, A.; Sato, T.; Nemoto, K.; Kamioka, H.; Hakeda, Y.; Kumegawa, M. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem., 1994, 269, 1106-1109.
12. Brömme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. J. Biol. Chem., 1996, 271, 2126-2132.
13. Drake, F. H.; Dodds, R. A.; James, I. E.; Connor, J. R.; Debouck, C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem., 1996, 271, 12511-12516.
14. Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Moritz, J. D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K deficient mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 13453-13458.
15. Gelb, B. D.; Shi, G.-P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science, 1996, 273, 1236-1238.
16. Inui, T.; Ishibashi, O.; Inaoka, T.; Origane, Y.; Kumegawa, M.; Kokubo, T.; Yamamura, T. Cathepsin K antisense oligodeoxy-nucleotide inhibits osteoclastic bone resorption. J. Biol. Chem., 1997, 272, 8109-8112.
17. Garnero, P.; Borel, O.; Byrjalsen, I.; Ferreras, M.; Drake, F. H.; McQueney, M. S.; Foged, N. T.; Delmas, P. D.; Delaissé, J-M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem., 1998, 273, 32347-32352.
18. Van Beek, E.; Pieterman, E.; Cohen, L.; Lowik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochme. Biophys. Res. Commun., 1999, 264, 108-111.
19. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen- containing bisphosphonates. J. Pharmacol. Exp. Ther., 2001, 296, 235-242.
20. Grabowska, U. B.; Chambers, T. J.; Shiroo, M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Dev., 2005, 8, 619-630.
21. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov., 2006, 5, 785-799.
22. Stoch, S. A.; Wagner, J. A. Cathepsin K Inhibitors: A novel target for osteoporosis therapy. Clin. Pharmacol. Ther., 2008, 83, 172-176.
23. Teno, N.; Kometani, M.; Betschart, C.; Toriyama, K.; Niwa, S.; Sakaki, J.; Altmann, E.; Buhl, T.; Gamse, R.; Gasser, J.A.; Lattmann, R.; Missbach, M. Abstracts of Papers, 12th Annual Meeting of Division of Medicinal Chemistry, Tsukuba, Japan, Nov 24-26, 2004, The Pharmaceutical Society of Japan, 2004, P1-28.
24. Moon, J. B.; Coleman, R. S.; Hanzlik, R. P. Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc., 1986, 108, 1350-1351.
25. Altmann, E.; Cowan-Jacob, S. W.; Missbach, M. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K. J. Med. Chem., 2004, 47, 5833-5836.
26. Altmann, E.; Aichholz, R.; Betschart, C.; Green, T.G.; Irie, O.; Teno, N.; Lattmann, R.; Tintelnot-Blomley, M.; Missbach, M. 2-Cyano-pyrimidines: A new chemotype for inhibitors of the cysteine protease cathepsin K. J. Med. Chem., 2007, 50, 591-594.
27. Teno, N.; Miyake, T.; Ehara, T.; Irie, O.; Sakaki, J.; Ohmori, O.; Gunji, H.; Matsuura, N.; Masuya, K.; Hitomi, Y.; Nonomura, K.; Horiuchi, M.; Gohda, K.; Iwasaki, A.; Umemura, I.; Tada, S.; Kometani, M.; Iwasaki, G.; Cowan-Jacob, S.W.; Missbach, M.; Lattmann, R.; Betschart, C. Novel scaffold for cathepsin K inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6096-6100.
28. Teno, N.; Irie, O.; Miyake, T.; Gohda, K.; Horiuchi, M.; Tada, S.; Nonomura, K.; Kometani, M.; Iwasaki, G.; Betschart, C. New chemotypes for cathepsin K inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2599-2603.
29. Teno, N.; Masuya, K.; Ehara, T.; Kosaka, T.; Miyake, T.; Irie, O.; Hitomi, Y.; Matsuura, N.; Umemura, I.; Iwasaki, G.; Fukaya, H.; Toriyama, K.; Uchiyama, N.; Nonomura, K.; Sugiyama, I.; Kometani, M. Effect of cathepsin K inhibitors on bone resorption. J. Med. Chem., 2008, 51, 5459-5462.
30. Robichaud, J.; Oballa, R.; Prasit, P.; Falgueyret, J-P.; Percival, M. D.; Wesolowski, G.; Rodan, S. B.; Kimmel, D.; Johnson, C.; Bryant, C.; Venkatraman, S.; Setti, E.; Mendonca, R.; Palmer, J. T. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J. Med. Chem., 2003, 46, 3709-3727.
31. Loeser, R.; Schilling, K.; Dimmig, E.; Guetschow, M. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J. Med. Chem., 2005, 48, 7688-7707.
32. Setti, E. L.; Venkatraman, S.; Palmer, J. T.; Xie, X.; Cheung, H.; Yu, W.; Wesolowski, G.; Robichaud, J. Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K. Bioorg. Med. Chem. Lett., 2006, 16, 4296-4299.
33. Patterson, A. W.; Wood, W. J. L.; Hornsby, M.; Lesley, S.; Spraggon, G.; Ellman, J. A. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J. Med. Chem., 2006, 49, 6298-6307.
34. Robichaud, J.; Black, W. C.; Therien, M.; Paquet, J.; Oballa, R. M.; Bayly, C. I.; McKay, D. J.; Wang, Q.; Isabel, E.; Leger, S.; Mellon, C.; Kimmel, D. B.; Wesolowski, G.; Percival, M. D.; Masse, F.; Desmarais, S.; Falgueyret, J-P.; Crane, S. N. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. J. Med. Chem., 2008, 51, 6410-6420.
35. Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.; Amegadzie, B. Y.; Hanning, C. R.; Jones, C.; Kurdyla, J. T.; McNulty, D. E.; Drake, F. H.; Gowen, M.; Levy, M. A. Proteolytic activity of human osteoclast cathepsin K. J. Biol. Chem., 1996, 271, 12517-12524.
36. Nosaka, A. Y.; Kanaori, K.; Teno, N.; Togame, H.; Inaoka, T.; Takai, M.; Kokubo, T. Conformational studies on the specific cleavage site of type I collagen (-1) fragment (157-192) by cathepsins K and L by proton NMR spectroscopy. Bioorg. Med. Chem., 1999, 7, 375-379.
37. Garnero, P.; Borel, O.; Byrjalsen, I.; Ferreras, M.; Drake, F.H.; McQueney, M. S.; Foged, N. T.; Delmas, P. D.; Delaisse, J. M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem., 1998, 273, 32347-32352.
38. Oballa, R. M.; Truchon, J. -F.; Bayly, C. I.; Chauret, N.; Day, S.; Crane, S.; Berthelette, C. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile- containing compounds. Bioorg. Med. Chem. Lett., 2007, 17, 998-1002.
39. McGrath, M. E.; Klaus, J. L.; Barnes, M. G.; Brömme, D. Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol., 1997, 4, 105-109.
40. Zhao, B.; Janson, C.A.; Amegadzie, B.Y.; D'Alessio, K.; Griffin, C.; Hanning, C.R.; Jones, C.; Kurdyla, J.; McQueney, M.; Qiu, X.; Smith, W.W.; Abdel-Meguid, S.S. Crystal structure of human osteoclast cathepsin K complex with E-64. Nat. Struct. Biol., 1997, 4, 109-111.
41. Chowdhury, S. F.; Sivaraman, J.; Wang, J.; Devanathan, G.; Lachance, P.; Qi, H.; Ménard, R.; Lefebvre, J.; Konishi, Y.; Cygler, M.; Sulea, T.; Purisima, E. O. Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides. J. Med. Chem., 2002, 45, 5321-5329.
42. Pauly, T. A.; Sulea, T.; Ammirati, M.; Sivaraman, J.; Danley, D. E.; Griffor, M. C.; Kamath, A. V.; Wang, I.-K.; Laird, E. R.; Seddon, A. P.; Menard, R.; Cygler, M.; Rath, V. L. Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry, 2003, 42, 3203-3213.
43. Lecaille, F.; Choe, Y.; Brandt, W.; Li, Z.; Craik, C. S.; Brömme, D. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry, 2002, 41, 8447-8454.
44. Lecaille, F.; Weidauer, E.; Juliano, M. A.; Bromme, D.; Lalmanach, G. Probing cathepsin K activity with a selective substrate spanning its active site. Biochem. J., 2003, 375, 307-312.
45. Alves, M. F.; Puzer, L.; Cotrin, S. S.; Juliano, M. A.; Juliano, L.; Brömme, D.; Carmona, A. K. S3 to S30 subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. Biochem. J., 2003, 373, 981-986.
46. Thompson, S. K.; Halbert, S. M.; Bossard, M. J.; Tomaszek, T. A.; Levy, M. A.; Zhao, B.; Smith, W. W.; Abdel-Meguid, S. S.; Janson, C. A.; D'Alessio, K. J.; McQueney, M. S.; Amegadzie, B. Y.; Hanning, C. R.; DesJarlais, R. L.; Briand, J.; Sarkar, S. K.; Huddleston, M. J.; Ijames, C. F.; Carr, S. A.; Garnes, K. T.; Shu, A.; Heys, J. R.; Bradbeer, J.; Zembryki, D.; Lee-Rykaczewski, L.; James, I. E.; Lark, M. W.; Drake, F. H.; Gowen, M.; Gleason, J. G.; Veber, D. F. Design of potent and selective human cathepsin K inhibitors that span the active site. Proc. Natl Acad. Sci. USA, 1997, 94, 14249-14254.
47. Hernandez, A. A.; Roush, W. R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol., 2002, 6, 459-465.
48. Kafienah, W.; Brömme, D.; Buttle, D. J.; Croucher, L. J.; Hollander, A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J., 1998, 331, 727-732.
49. Inaoka, T.; Bilbe, G.; Ishibashi, O.; Tezuka, K.; Kumegawa, M.; Kokubo, T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun., 1995, 206, 89-96.
50. Stephens, R. D.; Castro, C. E. The substitution of aryl iodides with cuprous acetylides. A synthesis of tolanes and heterocyclics. J. Org. Chem., 1963, 28, 3313-3315.
51. Kondo, Y.; Watanabe, R.; Sakamoto, T.; Yamanaka, H. Condensed heteroaromatic ring systems. XVI.: Synthesis of pyrrolo [2, 3-d]pyrimidine derivatives. Chem. Pharm. Bull., 1989, 37, 2933-2936.
52. Lu, Y.; Sakamuri, S.; Chen, Q. Z.; Keng, Y. F.; Khazak, V.; Illgen, K.; Schabbert, S.; Weber, L.; Menon, S. R. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg. Med. Chem. Lett., 2004, 14, 3957-3962.
53. Edwards, P. HIV-1 protease inhibitors. Drug Discov. Today, 2001, 6, 437-439.
54. Paradis-Bleaua, C.; Beaumontb, M.; Sanschagrina, F.; Voyerb, N.; Levesque, R. C. Parallel solid synthesis of inhibitors of the essential cell division FtsZ enzyme as a new potential class of antibacterials. Bioorg. Med. Chem., 2007, 15, 1330-1340.
55. Golebiowski, A.; Klopfenstein, S. R.; Portlock, D. E. Lead compounds discovered from libraries: Part 2. Curr. Opin. Chem. Biol., 2003, 7, 308-325.
56. Kumar, S.; Dare, L.; Vasko-Moser, J. A.; James, I. E.; Blake, S. M.; Rickard, D. J.; Hwang, S.-M.; Tomaszek, T.; Yamashita, D. S.; Marquis, R. W.; Oh, H.; Jeong, J. U.; Veber, D. F.; Gowen, M.; Lark, M. W.; Stroup, G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone, 2007, 40, 122-131.
57. Tavares, F. X.; Boncek, V.; Deaton, D. N.; Hassell, A. M.; Long, S. T.; Miller, A. B.; Payne, A. A.; Miller, L. R.; Shewchuk, L. M.; Wells-Knecht, K.; Willard, D. H.; Wright, L. L.; Zhou, H. Q. Design of potent, selective, and orally bioavailale inhibitors of cysteine protease cathepsin K. J. Med. Chem., 2004, 47, 588-599.
58. Lark, M. W.; Stroup, G. B.; James, I. E.; Dodds, R. A.; Hwang, S. M.; Blake, S. M.; Lechowska, B. A.; Hoffman, S. J.; Smith, B. R.; Kapadia, R.; Liang, X.; Erhard, K.; Ru, Y.; Dong, X.; Marquis, R. W.; Veber, D.; Gowen, M. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone metarix resorption in the ovariectomized rat. Bone, 2002, 30, 746-753.
59. Marquis, R. W.; Ru, Y.; LoCastro, S. M.; Zeng, J.; Yamashita, D. S.; Oh, H. J.; Erhard, K. F.; Davis, L. D.; Tomaszek, T. A.; Tew, D.; Salyers, K.; Proksch, J.; Ward, K.; Smith, B.; Levy, M.; Cummings, M. D.; Haltiwanger, R. C.; Trescher, G.; Wang, B.; Hemling, M. E.; Quinn, C. J.; Cheng, H. Y.; Lin, F.; Smith, W. W.; Janson, C. A.; Zhao, B.; McQueney, M. S.; D'Alessio, K.; Lee, C. P.; Marzulli, A.; Dodds, R. A.; Blake, S.; Hwang, S. M.; James, I. E.; Gress, C. J.; Bradley, B. R.; Lark, M.W.; Gowen, M.; Veber, D. F. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem., 2001, 44, 1380-1395.
60. Tada, S.; Tsutsumi, K.; Ishihara, H.; Suzukiz, K.; Gohda, K.; Teno, N. Species differences between human and rat in the substrate specificity of cathepsin K. J. Biochem., 2008, 144, 499-506.
61. Baron, R. Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec., 1989, 224, 317-324.
62. Blair, H. C.; Teitelbaum, S. L.; Ghiselli, R.; Gluck, S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science, 1989, 245, 855-857.
63. Mundy, G.; Garrett, R.; Harris, S.; Chan, J.; Chen, D.; Rossini, G.; Boyce, B.; Zhao, M.; Gutierrez, M. Stimulation of bone formation in vitro and in rodents by statins. Science, 1999, 286, 1946-1949.
64. Edwards, C. J.; Hart, D. J.; Spector, T. D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet, 2000, 355, 2218-2219.
65. Irie, O.; Ehara, T.; Iwasaki, A.; Yokokawa, F.; Sakaki, J.; Hirano, H.; Kanazawa, T.; Teno, N.; Horiuchi, M.; Umemura, I.; Gunji, H.; Masuya, K.; Hitomi, Y.; Iwasaki, G.; Nonomura, K.; Tanabe, K.; Fukaya, H.; Kosaka, T.; Snell, C. R.; Hallett, A. Discovery of selective and nonpeptidic cathepsin S inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 3959-3962.
66. Irie, O, Kosaka, T, Ehara, T.; Yokokawa, F.; Kanazawa, T.; Hirao, H.; Iwasaki, A.; Sakaki, J.; Teno, N.; Hitomi, Y.; Iwasaki, G.; Fukaya, H.; Nonomura, K.; Tanabe, K.; Koizumi, S.; Uchiyama, N.; Bevan, S. J.; Malcangio, M.; Gentry, C.; Fox, A. J.; Yaqoob, M.; Culshaw, A. J.; Hallett, A. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. J. Med. Chem., 2008, 51, 5502-5505.
67. Irie, O.; Yokokawa, F.; Ehara, T.; Iwasaki, A.; Iwaki, Y.; Hitomi, Y.; Konishi, K.; Kishida, M.; Toyao, A.; Masuya, K.; Gunji, H.; Sakaki, J.; Iwasaki, G.; Hirao, H.; Kanazawa, T.; Tanabe, K.; Kosaka, T.; Hart, T. W.; Hallett, A. 4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4642-4646.
68. Irie, O.; Kosaka, T.; Kishida, M.; Sakaki, J.; Masuya, K.; Konishi, K.; Yokokawa, F.; Ehara, T.; Iwasaki, A.; Iwaki, Y.; Hitomi, Y.; Toyao, A.; Gunji, H.; Teno, N.; Iwasaki, G.; Hirao, H.; Kanazawa, T.; Tanabe, K.; Hiestand, P. C.; Malcangio, M.; Fox, A. J.; Bevan, S. J.; Yaqoob, M.; Culshaw, A. J.; Hart, T. W.; Hallett, A. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2. Bioorg. Med. Chem. Lett., 2008, 18, 5280-5284.